

**Amendments to the Claims**

**1. (Previously presented)** A pharmaceutical agent having serotonin 5-HT<sub>7</sub> receptor antagonist activity and muscarinic M<sub>4</sub> receptor agonist activity, for use in treating psychotic conditions, wherein the agent does not include compounds having a chemical structure falling within the following definition, namely:

bisarylazepines substituted at the azepine ring portion by a 4-methyl piperazinyl, wherein the aryl moieties are fused to the azepine ring and wherein aryl is phenyl, substituted phenyl, thienyl or substituted thienyl; including optional replacement of an azepine ring carbon atom with a nitrogen atom, or substitution of said ring carbon atom.

**2. (Original)** The pharmaceutical agent according to claim 1 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

**3. (Previously presented)** The pharmaceutical agent according to claim 1 which comprises a mixture of at least two compounds, wherein at least one of said compounds possesses serotonin 5-HT<sub>7</sub> receptor antagonist activity and wherein at least one of said compounds possesses muscarinic M<sub>4</sub> receptor agonist activity.


**4. (Previously presented)** The pharmaceutical agent according to claim 1 which comprises a compound which possesses both serotonin 5-HT<sub>7</sub> receptor antagonist activity and muscarinic M<sub>4</sub> receptor agonist activity.

**5. (Previously presented)** The pharmaceutical agent according to claim 1 which additionally has a low or substantially no dopaminergic D<sub>2</sub> receptor affinity.


**6. (Original)** The pharmaceutical agent according to claim 5 wherein said dopaminergic D<sub>2</sub> receptor affinity is a minimum of at least 5 fold less than the affinity at the muscarinic M<sub>4</sub> and/or serotonin 5-HT<sub>7</sub> receptors.

- 7. (Original)** The pharmaceutical agent according to claim 6 wherein said dopaminergic D<sub>2</sub> receptor affinity is at least 50 fold less than the affinity at the muscarinic M<sub>4</sub> and/or serotonin 5-HT<sub>7</sub> receptors.
- 8. (Previously presented)** A pharmaceutical agent according to claim 1 for use in therapy.
- 9. (Previously presented)** A pharmaceutical formulation comprising a pharmaceutical agent according to claim 1 together with a pharmaceutically acceptable carrier therefor.
- 10. (Previously presented)** A method for the preparation of a medicament for the treatment or prophylaxis of schizophrenia and/or bipolar disorder, which comprises mixing the pharmaceutical agent according to claim 1 with a pharmaceutically acceptable carrier.
- 11. (Previously presented)** A method of treating psychotic conditions in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical agent according to claim 1.
- 12. (Previously presented)** A method of identifying an agent for use in treating psychotic conditions comprising the steps of:
- a) providing an agent to be tested;
  - b) subjecting said agent to one or more test procedures to identify 5-HT<sub>7</sub> receptor antagonist activity and muscarinic M<sub>4</sub> receptor agonist activity of said agent; wherein the desired agent is considered to have been identified when said agent provides a 5-HT<sub>7</sub> receptor antagonist activity and a muscarinic M<sub>4</sub> receptor agonist activity.
- 13. (Original)** The method according to claim 12 further comprising the step of subjecting the agent to a test procedure to identify low dopaminergic D<sub>2</sub> receptor affinity.

**14. (Currently amended)** A compound represented by formula (I):



where  $R^1$  and  $R^2$  independently are a hydrogen atom, a substituted or unsubstituted straight chain or branched chain  $C_{1-6}$  alkyl group or  $C_{1-6}$  alkoxy group, a substituted or unsubstituted  $C_{3-8}$  cycloalkyl group or a  $C_{3-8}$  cycloalkoxy group, or an aralkyl group, or  $R^1$  and  $R^2$  form, together with the nitrogen atom to which they are bonded, a cyclic amine which is substituted by a halogen atom, a  $C_{1-6}$  alkyl group or a  $C_{1-6}$  alkoxy group and/or wherein said cyclic amine is fused with a benzene ring; W and W' form, together with the benzene ring to which they are bonded, a fused five-membered, six-membered or seven-membered saturated carbocyclic ring being independently unsubstituted, substituted or fully substituted at each carbon atom of the ring by a group  $-X-R^{13}$  where X is O, S, SO or  $SO_2$  and  $R^{13}$  is a hydrogen atom, a  $C_{1-6}$  alkyl group, an acyl group, or an aroyl group or two of said  $-X-R^{13}$  groups, together with the carbon atom in the ring to which they are both bonded, form a C=S group or the following group:






where both of X' are O or S and Y is a  $C_{1-3}$  alkylene group.

**15. (Canceled)**


**16. (Canceled)**

**17. (Currently amended)** The compound according to claim ~~16~~14 wherein said benzene ring fused with said cyclic amine is substituted by one or two halogen atoms, C<sub>1-6</sub> alkyl groups or C<sub>1-6</sub> alkoxy groups.

**18. (Currently amended)** The compound according to claim 14 represented by the following formulae (II), (III) -or (IV):




wherein  $R^1$  and  $R^2$  independently are a hydrogen atom, a substituted or unsubstituted straight chain or branched chain  $C_{1-6}$  alkyl group or  $C_{1-6}$  alkoxy group, a substituted or unsubstituted  $C_{1-6}$  cycloalkyl group or a  $C_{1-6}$  cycloalkoxy group, or an aralkyl group, or  $R^1$  and  $R^2$  form, together with the nitrogen atom to which they are bonded, a cyclic amine which is substituted by a halogen atom, a  $C_{1-6}$  alkyl group or a  $C_{1-6}$  alkoxy group and/or wherein said cyclic amine is fused with a benzene ring;  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently a hydrogen atom or the group  $-X-R^{13}$  wherein X is O, S, SO or  $SO_2$  and  $R^{13}$  is a hydrogen atom, a  $C_{1-6}$  alkyl group, an acyl group, or an aroyl group or two of said  $-X-R^{13}$  groups, together with the carbon atom in the ring to which they are both bonded, form a C=S group or the following group:



where both of  $X'$  are O or S and Y is a  $C_{1-3}$  alkylene group.

**19. (Previously presented)** The compound according to claim 18 wherein  $R^3$  and  $R^4$ ,  $R^5$  and  $R^6$ ,  $R^7$  and  $R^8$ ,  $R^9$  and  $R^{10}$ , and/or  $R^{11}$  and  $R^{12}$  together with the carbon atom in the ring to which they are both bonded, form a C=S group or the following group:



wherein both of  $X'$  are O or S and Y is a  $C_{1-3}$  alkylene group.

**20. (Previously presented)** The compound according to claim 18 wherein  $R^1$  and  $R^2$  form together with the nitrogen atom to which they are bonded, a four-membered, five-membered or six-membered cyclic amine.

**21. (Original)** A compound according to claim 20 wherein said six-membered cyclic amine is fused with a benzene ring.

**22. (Canceled)**

**23. (Previously presented)** The compound according to claim 14 which possesses serotonin 5-HT<sub>7</sub> receptor antagonist activity and/or muscarinic M<sub>4</sub> receptor agonist activity.

**24. (Currently amended)** The compound according to claim 23 which additionally has a low or ~~substantially~~-no dopaminergic D<sub>2</sub> receptor affinity.

**25. (Previously presented)** The compound according to claim 14 for use in therapy.

**26. (Previously presented)** A pharmaceutical formulation comprising a compound according to claim 14 admixed with a pharmaceutically acceptable carrier.

**27. (Previously presented)** A method for the preparation of a medicament for the treatment or prophylaxis of schizophrenia and/or bipolar disorder, which comprises mixing the compound according to claim 14 with a pharmaceutically acceptable carrier.

**28. (Previously presented)** A method of treating psychotic conditions in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to claim 14 .

**29. (Previously presented)** The pharmaceutical agent according to claim 3 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

**30. (Previously presented)** The pharmaceutical agent according to claim 4 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

- 31. (Previously presented)** The pharmaceutical agent according to claim 5 wherein the psychotic condition is schizophrenia and/or bipolar disorder.
- 32. (Previously presented)** The pharmaceutical agent according to claim 6 wherein the psychotic condition is schizophrenia and/or bipolar disorder.
- 33. (Previously presented)** The pharmaceutical agent according to claim 7 wherein the psychotic condition is schizophrenia and/or bipolar disorder.
- 34. (Previously presented)** The pharmaceutical agent according to claim 8 for use in therapy for schizophrenia and/or bipolar disorder.
- 35. (Previously presented)** The pharmaceutical formulation according to claim 9 for use in therapy for schizophrenia and/or bipolar disorder.
- 36. (Previously presented)** The method according to claim 11 wherein the psychotic condition is schizophrenia and/or bipolar disorder.
- 37. (Previously presented)** The compound according to claim 19 wherein  $R^1$  and  $R^2$  form together with the nitrogen atom to which they are bonded, a four-membered, five-membered or six-membered cyclic amine.
- 38. (Previously presented)** The compound according to claim 37 wherein said six-membered cyclic amine is fused with a benzene ring.
- 39. (Previously presented)** The method according to claim 28 wherein the psychotic condition is schizophrenia and/or bipolar disorder.